secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096127
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024
-----------------------------------------------------------------------

- Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
- R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.
- Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.
- General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/0000950170-24-096127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017024096127/rphm-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer